Lynn Bodarky Joins HiFiBiO Therapeutics as SVP, Global Head of Business Development and Alliance Management May 9, 2022 By sarahjibrin
Apr 27, 2022 By sarahjibrin HiFiBiO Therapeutics to Present Trial in Progress Poster for HFB200301 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 18, 2022 By sarahjibrin HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatment
Apr 18, 2022 By sarahjibrin Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumors
Apr 18, 2022 By sarahjibrin Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization
Apr 12, 2021 By sarahjibrin Clinical approach and biomarker strategy for HFB301001, a novel OX40 agonistic antibody
Apr 12, 2021 By sarahjibrin HFB9-2, a novel Galectin 9 neutralizing antibody for the treatment of AML and other cancers
Apr 12, 2021 By sarahjibrin Mechanism of Action and Biomarker Strategy for HFB200301, an Anti-TNFR2 Agonist Antibody for the Treatment of Cancer
Apr 12, 2021 By sarahjibrin Discovery and characterization of a novel anti-human CXCR5 antibody for the treatment of B cell lymphomas
Jul 3, 2020 By sarahjibrin HFB9-2, a novel Galectin-9 neutralizing antibody to reverse immune suppression in the tumor microenvironment
Jul 3, 2020 By sarahjibrin Discovery and characterization of novel TNFR2 antibodies to modulate T cell activities in immunosuppressive environment
